Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Caoshi Silkworm Granule is a Traditional Chinese Medicine (TCM) hospital preparation developed by Jinhua Municipal Central Hospital for the treatment of chronic obstructive pulmonary disease (COPD). The formulation is primarily based on the herb *Stachys sieboldii* (known as Caoshican or Chinese artichoke), which is traditionally used in TCM to clear heat, detoxify, and resolve phlegm. It is specifically indicated for COPD patients presenting with the 'phlegm-heat obstructing the lungs' pattern. Clinical research conducted by the developer suggests that the granule improves pulmonary function parameters, such as FEV1/FVC, and reduces systemic inflammatory markers, including Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-8 (IL-8). The drug is typically used during the stable phase of COPD to prevent exacerbations or during acute phases to alleviate symptoms like cough and excessive sputum.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound caoshi silkworm granule.